Company intelligence / Profile preview

Perlan Therapeutics

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

Perlan Therapeutics was a clinical-stage biotechnology company focused on developing novel therapies for respiratory viral infections. The company's lead program, PTX-001, was a recombinant human soluble Intercellular Adhesion Molecule-1 (rhICAM-1) designed to treat the common cold by acting as a decoy receptor for rhinoviruses. By binding to the virus before it could attach to nasal epithelial cells, the therapy aimed to reduce the severity and duration of symptoms. Perlan advanced its lead candidate through Phase 2 clinical trials before being acquired by Biota Pharmaceuticals in 2012 to bolster their respiratory antiviral pipeline.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Perlan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perlan Therapeutics.

Explore the full profile